Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1456349

registered interest
date	31/03/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of patients who are eligible for biologic treatment for severe asthma who are not currently accessing it.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	151058
answer	answer is ministerial correction date of answer 19/04/2022 answer text <p>The NHS England and NHS Improvement Accelerated Access Collaborative (AAC) on Improving Access to Biologic Therapy estimates that approximately 200,000 or 5% of patients with asthma have severe asthma. Of these patients, the AAC estimates that between 50,000 to 100,000 may be eligible for biologic therapy, with approximately 11,000 patients receiving this treatment. The AAC aims to improve the identification of these patients in primary and secondary care settings, to allow referrals to specialist severe asthma centres to determine their suitability for biologic treatment.</p><p>No specific estimate of the number of patients awaiting an appointment at a severe asthma centre has been made as this information is not collected in the format requested. No specific assessment has been made of the effectiveness of home administration of biologics for severe asthma. The National Institute for Health and Care Excellence’s COVID-19 rapid guideline on severe asthma promoted the use of home administration for biologic treatments to maintain access and reduce risks to patients of COVID-19 exposure. While we are ensuring that patients who are eligible for this treatment are able to access it, there are no plans to extend the eligibility criteria.</p> answering member constituency Chichester answering member printed Gillian Keegan grouped question UIN 151059 151060 question first answered 19/04/2022 11:47:25 answering member 4680 label Biography information for Gillian Keegan
tabling member	4034 label Biography information for Yvonne Fovargue

1456350

registered interest
date	31/03/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of patients awaiting an appointment at a severe asthma centre.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	151059
answer	answer is ministerial correction date of answer 19/04/2022 answer text <p>The NHS England and NHS Improvement Accelerated Access Collaborative (AAC) on Improving Access to Biologic Therapy estimates that approximately 200,000 or 5% of patients with asthma have severe asthma. Of these patients, the AAC estimates that between 50,000 to 100,000 may be eligible for biologic therapy, with approximately 11,000 patients receiving this treatment. The AAC aims to improve the identification of these patients in primary and secondary care settings, to allow referrals to specialist severe asthma centres to determine their suitability for biologic treatment.</p><p>No specific estimate of the number of patients awaiting an appointment at a severe asthma centre has been made as this information is not collected in the format requested. No specific assessment has been made of the effectiveness of home administration of biologics for severe asthma. The National Institute for Health and Care Excellence’s COVID-19 rapid guideline on severe asthma promoted the use of home administration for biologic treatments to maintain access and reduce risks to patients of COVID-19 exposure. While we are ensuring that patients who are eligible for this treatment are able to access it, there are no plans to extend the eligibility criteria.</p> answering member constituency Chichester answering member printed Gillian Keegan grouped question UIN 151058 151060 question first answered 19/04/2022 11:47:25 answering member 4680 label Biography information for Gillian Keegan
tabling member	4034 label Biography information for Yvonne Fovargue

1456351

registered interest
date	31/03/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of home administration of biologics for severe asthma; and whether he has plans to extend that treatment.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	151060
answer	answer is ministerial correction date of answer 19/04/2022 answer text <p>The NHS England and NHS Improvement Accelerated Access Collaborative (AAC) on Improving Access to Biologic Therapy estimates that approximately 200,000 or 5% of patients with asthma have severe asthma. Of these patients, the AAC estimates that between 50,000 to 100,000 may be eligible for biologic therapy, with approximately 11,000 patients receiving this treatment. The AAC aims to improve the identification of these patients in primary and secondary care settings, to allow referrals to specialist severe asthma centres to determine their suitability for biologic treatment.</p><p>No specific estimate of the number of patients awaiting an appointment at a severe asthma centre has been made as this information is not collected in the format requested. No specific assessment has been made of the effectiveness of home administration of biologics for severe asthma. The National Institute for Health and Care Excellence’s COVID-19 rapid guideline on severe asthma promoted the use of home administration for biologic treatments to maintain access and reduce risks to patients of COVID-19 exposure. While we are ensuring that patients who are eligible for this treatment are able to access it, there are no plans to extend the eligibility criteria.</p> answering member constituency Chichester answering member printed Gillian Keegan grouped question UIN 151058 151059 question first answered 19/04/2022 11:47:25 answering member 4680 label Biography information for Gillian Keegan
tabling member	4034 label Biography information for Yvonne Fovargue

1419854

registered interest
date	04/02/2022
answering body	Department for Digital, Culture, Media and Sport
answering dept id	10
answering dept short name	Digital, Culture, Media and Sport
answering dept sort name	Digital, Culture, Media and Sport
hansard heading	Smart Devices: Electronic Commerce
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Digital, Culture, Media and Sport, whether smart products sold on online marketplaces will be subject to the provisions of the Product Security and Telecommunications Infrastructure Bill.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	118527
answer	answer is ministerial correction date of answer 09/02/2022 answer text <p>Security requirements to be set out using the powers in the Product Security and Telecommunications Infrastructure Bill will have to be complied with relation to all relevant consumer connectable products sold to customers in the UK, including those sold on online marketplaces.</p> answering member constituency Hornchurch and Upminster answering member printed Julia Lopez question first answered 09/02/2022 14:02:47 answering member 4647 label Biography information for Julia Lopez
tabling member	4034 label Biography information for Yvonne Fovargue

1419855

registered interest
date	04/02/2022
answering body	Department for Digital, Culture, Media and Sport
answering dept id	10
answering dept short name	Digital, Culture, Media and Sport
answering dept sort name	Digital, Culture, Media and Sport
hansard heading	Smart Devices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Digital, Culture, Media and Sport, whether she plans to include provisions for when a smart product is recalled within the Product Security and Telecommunications Infrastructure Bill.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	118528
answer	answer is ministerial correction date of answer 09/02/2022 answer text <p>The Product Security and Telecommunications Infrastructure Bill includes provisions that allow the Secretary of State to issue recall notices relating to relevant insecure consumer connected products, if deemed appropriate.</p> answering member constituency Hornchurch and Upminster answering member printed Julia Lopez question first answered 09/02/2022 14:04:25 answering member 4647 label Biography information for Julia Lopez
tabling member	4034 label Biography information for Yvonne Fovargue

1387201

registered interest
date	13/12/2021
answering body	Ministry of Justice
answering dept id	54
answering dept short name	Justice
answering dept sort name	Justice
hansard heading	Enforcement
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Justice, what steps the Government has taken to support the establishment of the Enforcement Conduct Authority proposed by Centre for Social Justice; and when his Department plans to publish the results of its 2018 call for evidence on enforcement agent reforms.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	91951
answer	answer is ministerial correction date of answer 20/12/2021 answer text <p>The Ministry of Justice strongly supports the creation of the independent oversight body for enforcement agents and firms that has been proposed by the Centre for Social Justice (CSJ). Officials have met regularly with the CSJ and the working group that is establishing the body to support its development. We will undertake a review of the body within two years of its operation to see if any legislative changes are necessary to place it on a statutory footing.</p><p>The publication of the response to our call for evidence about the enforcement agent reforms, which closed in February 2019, has been delayed as a result of the department’s response to the pandemic. That allowed us to refocus our priorities, which resulted, for example, in MoJ and DLUHC introducing an extended ban on enforcing evictions to prevent people being made homeless during Covid, so protecting public health and easing the burden on the NHS and local authorities.</p><p>We remain committed to raising standards in this sector and will publish the response as soon as possible.</p> answering member constituency South Suffolk answering member printed James Cartlidge question first answered 20/12/2021 16:23:33 answering member 4519 label Biography information for James Cartlidge
tabling member	4034 label Biography information for Yvonne Fovargue

1353444

registered interest
date	07/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the size of the eligible population among severe asthma suffers for biologic treatments.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	44318
answer	answer is ministerial correction date of answer 16/09/2021 answer text <p>No estimate has been made and information on the number of severe asthma patients are receiving biologic therapies is not available in the format requested.</p><p> </p><p> </p><p>Clinicians are responsible for making prescribing decisions for their patients, taking into account the National Institute for Health and Care Excellence’s technology appraisals and guidance on management of asthma and the local commissioning decisions. Prescribing of biologics for severe asthma is co-ordinated through severe asthma centre multi-disciplinary teams to ensure current treatments are optimised and all appropriate treatments are considered with use of biologics as part of the treatment review for each patient.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 44319 44320 question first answered 16/09/2021 15:01:18 answering member 4380 label Biography information for Jo Churchill
tabling member	4034 label Biography information for Yvonne Fovargue

1353445

registered interest
date	07/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many severe asthma patients are receiving biologic therapies through (a) the severe asthma networks and (b) other services.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	44319
answer	answer is ministerial correction date of answer 16/09/2021 answer text <p>No estimate has been made and information on the number of severe asthma patients are receiving biologic therapies is not available in the format requested.</p><p> </p><p> </p><p>Clinicians are responsible for making prescribing decisions for their patients, taking into account the National Institute for Health and Care Excellence’s technology appraisals and guidance on management of asthma and the local commissioning decisions. Prescribing of biologics for severe asthma is co-ordinated through severe asthma centre multi-disciplinary teams to ensure current treatments are optimised and all appropriate treatments are considered with use of biologics as part of the treatment review for each patient.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 44318 44320 question first answered 16/09/2021 15:01:18 answering member 4380 label Biography information for Jo Churchill
tabling member	4034 label Biography information for Yvonne Fovargue

1353446

registered interest
date	07/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce the geographical variation in the prescribing of biologics for severe asthma.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	44320
answer	answer is ministerial correction date of answer 16/09/2021 answer text <p>No estimate has been made and information on the number of severe asthma patients are receiving biologic therapies is not available in the format requested.</p><p> </p><p> </p><p>Clinicians are responsible for making prescribing decisions for their patients, taking into account the National Institute for Health and Care Excellence’s technology appraisals and guidance on management of asthma and the local commissioning decisions. Prescribing of biologics for severe asthma is co-ordinated through severe asthma centre multi-disciplinary teams to ensure current treatments are optimised and all appropriate treatments are considered with use of biologics as part of the treatment review for each patient.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 44318 44319 question first answered 16/09/2021 15:01:18 answering member 4380 label Biography information for Jo Churchill
tabling member	4034 label Biography information for Yvonne Fovargue

1353447

registered interest
date	07/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what help is available for asthma sufferers to enable them to continue to self-administer their medication due to the pressures on the NHS during the covid-19 outbreak.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	44321
answer	answer is ministerial correction date of answer 10/09/2021 answer text <p>Specialist respiratory services for severe asthma, along with urgent and emergency treatment for other serious complaints, have continued throughout the COVID-19 outbreak. In most cases people with severe asthma have been able to receive their medication at home instead of having to attend hospital.</p><p>The National Institute for Health and Care Excellence COVID-19 rapid guideline on severe asthma promoted the use of home delivery for biologic treatments to maintain access and reduce the risks to patients of COVID-19 exposure. The NHS England severe asthma ‘Accelerated Access Collaborative’ will continue to focus on the area of home administration.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 10/09/2021 13:13:49 answering member 4380 label Biography information for Jo Churchill
tabling member	4034 label Biography information for Yvonne Fovargue